Today is the first day of trading in DanCann Pharma A/S shares and warrants at Spotlight Stock Market
Today is the first day of trading in DanCann Pharma A/S ("DanCann Pharma") shares and warrants of series TO 1. DanCann Pharma’s shares are traded under the ticker "DANCAN" with ISIN DK0061410487 and DanCann Pharma’s warrants of series TO 1 are traded under the ticker "DANCAN TO 1" with ISIN DK0061410560.
DanCann Pharma was provided approximately DKK 30 million (before issue costs) in the oversubscribed IPO of units which resulted in more than 1 600 new shareholders. The total number of shares in DanCann Pharma is 20 730 800 shares and the share capital amount to DKK 777 405. In addition, there are a total of 2 668 000 warrants of series TO 1 issued. Each warrant of series TO 1 entitles the holder the right to subscribe for one (1) new share in DanCann Pharma at a subscription price of DKK 6 per share during the exercise period September 1, 2021 until September 17, 2021.
Financial advisor, legal advisor and issuing agent
Corpura Fondkommission AB is the financial advisor of DanCann Pharma in connection with the issue of units. Andersen Partners Advokatpartnerselskab is acting as legal advisor. Nordic Issuing is acting as issuing agent. For additional information regarding the IPO, please contact:
Corpura Fondkommission AB
About DanCann Pharma
DanCann Pharma was founded in 2018 and is a Danish pharmaceutical biotechnology company powered by cannabinoids. DanCann Pharma is a vertically integrated, licensed cultivation and distribution company based in Denmark. The company focuses on discovering, developing, manufacturing, and commercializing new therapeutic cannabinoids in a wide range of disease areas.
For further information, please contact:
Fluicell mottar sin andra köporder från Oblique Therapeutics AB avseende Dynaflow® Resolve-system
Fluicell AB (publ.) (“Fluicell” eller ”Bolaget”) meddelar härmed att Bolaget mottagit en köporder på ett Dynaflow® Resolve-system från det svenska biotechbolaget Oblique Therapeutics AB (”Oblique Therapeutics”). Detta är Fluicells andra försäljning under 2020 av ett Dynaflow® Resolve-system ti...
First day of trading with warrants of series TO4
As previously communicated, Cyxone AB (publ) (“Cyxone” or the “Company”) has resolved to allocate one (1) warrant of series TO4 to the Company’s existing shareholders for every twenty-eight (28) shares owned on the record date of November 19, 2020. The Warrants will, to some extent, compensate the c...
Första dag för handel i teckningsoptioner av serie TO4
Som tidigare kommunicerats har Cyxone AB (publ) (“Cyxone” eller “Bolaget”) beslutat att tilldela en (1) teckningsoption av serie TO4 till Bolagets befintliga aktieägare för varje tjugoåtta (28) ägda aktier per avstämningsdagen den 19 november 2020. Teckningsoptionerna kommer att, till viss del, komp...
Bulletin from the Extraordinary General Meeting in Magle Chemoswed on 27 November 2020
At the Extraordinary General Meeting in Magle Chemoswed Holding AB (publ) held on 27 November 2020, it was resolved to approve the Board’s resolution on a new share issue with pre-emptive rights for the shareholders of SEK 20 million, before transaction costs. Through the rights issue, not more than...